NANOSONICS LIMITED (NAN)
Share Price Analysis and Chart

Enter the company code or Name for stock analysis:

NAN

NAN - NANOSONICS LIMITED

FNArena Sector : Medical Equipment & Devices
Year End: June
GICS Industry Group : Health Care Equipment & Services
Debt/EBITDA: 0.31
Index: ASX200 | ASX300 | ALL-ORDS

Nanosonics is an Australian medical device company manufacturing high level disinfection systems to reduce the spread of infection. Founded in 2001, the company listed on the ASX in 2007.

LAST PRICE CHANGE +/- CHANGE % VOLUME

$3.25

26 Feb
2026

-0.130

OPEN

$3.40

-3.85%

HIGH

$3.40

1,280,950

LOW

$3.23

TARGET
$3.80 16.9% upside
OTHER COMPANIES IN THE SAME SECTOR
4DX . AT1 . AYA . BB1 . BRN . CAT . CBL . CGS . CMP . COH . CSX . CU6 . CVB . CYC . EBR . EMV . EYE . FPH . IME . IMR . IPD . LDX . MX1 . ONE . PCK . PEB . PGC . PME . RAP . RMD . SHG . SOM . TRJ . UBI .
FNARENA'S MARKET CONSENSUS FORECASTS
NAN: 1
Title FY24
Actual		 FY25
Actual		 FY26
Forecast		 FY27
Forecast
EPS (cps) xxx 6.8 5.6 xxx
DPS (cps) xxx 0.0 0.0 xxx
EPS Growth xxx 59.3% - 17.9% xxx
DPS Growth xxx N/A N/A xxx
PE Ratio xxx N/A 61.1 xxx
Dividend Yield xxx N/A 0.0% xxx
Div Pay Ratio(%) xxx N/A N/A xxx

Dividend yield today if purchased 3 years ago: 0.00%

DIVIDEND YIELD CALCULATOR

Dividend Yield Today On Last Actual Payout :

 0.00

Estimated Dividend Growth
(Average Of Past Three Years)

  %

Amount Invested

 $ 

Tell Me The Dividend After This Many Years
Past performance is no guarantee for the future. Investors should take into account that heavy swings in share price or exceptional circumstances (a la 2009) can have a significant impact on short term calculations and averages
HISTORICAL DATA ARE ALL IN AUD
Copyright © 2026 FactSet UK Limited. All rights reserved
Title 202020212022202320242025
EPS Basic xxxxxxxxxxxxxxx6.8
DPS All xxxxxxxxxxxxxxx0.0
Sales/Revenue xxxxxxxxxxxxxxx198.3 M
Book Value Per Share xxxxxxxxxxxxxxx69.1
Net Operating Cash Flow xxxxxxxxxxxxxxx44.0 M
Net Profit Margin xxxxxxxxxxxxxxx10.43 %

EPS Basic

DPS All

Sales/Revenue

Book Value Per Share

Net Operating Cash Flow

Net Profit Margin

Title 202020212022202320242025
Return on Capital Employed xxxxxxxxxxxxxxx10.55 %
Return on Invested Capital xxxxxxxxxxxxxxx10.27 %
Return on Assets xxxxxxxxxxxxxxx7.99 %
Return on Equity xxxxxxxxxxxxxxx10.55 %
Return on Total Capital xxxxxxxxxxxxxxx8.01 %
Free Cash Flow ex dividends xxxxxxxxxxxxxxx35.3 M

Return on Capital Employed

Return on Invested Capital

Return on Assets

Return on Equity

Return on Total Capital

Free Cash Flow ex dividends

Title 202020212022202320242025
Short-Term Debt xxxxxxxxxxxxxxx3 M
Long Term Debt xxxxxxxxxxxxxxx4 M
Total Debt xxxxxxxxxxxxxxx8 M
Goodwill - Gross xxxxxxxxxxxxxxx-
Cash & Equivalents - Generic xxxxxxxxxxxxxxx162 M
Price To Book Value xxxxxxxxxxxxxxx5.86

Short-Term Debt

Long Term Debt

Total Debt

Goodwill - Gross

Cash & Equivalents - Generic

Price To Book Value

Title 202020212022202320242025
Capex xxxxxxxxxxxxxxx8.7 M
Capex % of Sales xxxxxxxxxxxxxxx4.40 %
Cost of Goods Sold xxxxxxxxxxxxxxx50 M
Selling, General & Admin. Exp & Other xxxxxxxxxxxxxxx131 M
Research & Development xxxxxxxxxxxxxxx32 M
Investments - Total xxxxxxxxxxxxxxx2 M

Capex

Capex % of Sales

Cost of Goods Sold

Selling, General & Admin. Exp & Other

Research & Development

Investments - Total

EXPERT VIEWS
Display All Commentary

Sentiment Indicator

0.5

No. Of Recommendations

2
BROKER DATE RATING RECOMMENDATION TARGET PRICE % TO REACH TARGET COMMENTARY

Morgans

xx/xx/xxxx

1

xxx

$xx.xx

xx.xx%

Broker commentary and detailed analysis is available for Full Members Only.
Login above or Get a Free Trial

Bell Potter

25/02/2026

3

Upgrade to Hold from Sell

$3.60

10.77%

Nanosonics reported 1H26 revenues of $102.2m (consensus of $105m), up 9% year on year, while earnings of $8.5m were modestly ahead of consensus but only in line with the prior first half.

The US remained the powerhouse for revenue growth, Bell Potter notes, generating double digit percentage growth across capital sales and consumables

However, total revenues failed to exceed the prior sequential period for the first time since the end of the covid period due to the combination of currency headwinds and slowing consumables sales.

Target falls to $3.60 from $4.10, but Bell Potter upgrades to Hold from Sell based on valuation. In the broker's view the stock is oversold and the current market price represents a reasonable entry point.

FORECAST
Bell Potter forecasts a full year FY26 dividend of 0.00 cents and EPS of 5.20 cents.
Bell Potter forecasts a full year FY27 dividend of 0.00 cents and EPS of 6.10 cents.
Access Stockbroker Research History >
EXTRA COVERAGE
Display All Commentary

No. Of Recommendations

1

Please note: unlike Broker Call Report, BC Extra is not updated daily. The info you see might not be the latest. FNArena does its best to update ASAP.

BROKER DATE RATING RECOMMENDATION TARGET PRICE % TO REACH TARGET COMMENTARY

Canaccord Genuity

10/12/2025

1

Buy

$5.43

67.08%

Canaccord Genuity has transferred coverage of Nanosonics to Shane Storey due to an analyst departure and re-allocation of resources.

No change to Buy rating and $5.43 target.

FORECAST
Canaccord Genuity forecasts a full year FY26 dividend of 0.00 cents and EPS of 6.84 cents.
Canaccord Genuity forecasts a full year FY27 EPS of 11.36 cents.
Access Extra Coverage Research History >

NAN STOCK CHART

FNArena News on NAN

1
FNArena Corporate Results Monitor – 25-02-2026

Feb 25 2026 - Australia
2
Rudi’s View: February Favourites & Avoids

Jan 29 2026 - Rudi's View
3
Australian Broker Call *Extra* Edition – Dec 10, 2025

Dec 10 2025 - Daily Market Reports
4
Rudi’s View: Coles, GemLife, Harvey Norman, Lynas, Orica, Reece, Seek & More

Sep 18 2025 - Rudi's View
5
Australian Broker Call *Extra* Edition – Sep 03, 2025

Sep 03 2025 - Daily Market Reports

Latest Medical Equipment & Devices News

1
GLP-1s Drive Strong Quarter For ResMed

Feb 02 2026 - Australia
2
ImpediMed Ready To Scale Up

Dec 16 2025 - Small Caps
3
Fisher & Paykel Healthcare’s Superior Profile

Dec 02 2025 - Australia
4
4DMedical Poised For A Recovery

Nov 25 2025 - Technicals
5
Treasure Chest: Pro Medicus

Nov 12 2025 - Treasure Chest
6
Tariff Uncertainty Negates ResMed’s Q1 Positives

Nov 05 2025 - Australia
7
Acquisition Loads Up Catapult

Oct 20 2025 - Small Caps
8
Cochlear’s Future In Nexa’s Hands

Aug 19 2025 - Australia
9
ResMed’s New Level Of Support

Jul 29 2025 - Technicals
10
Strength To ‘AI’ Strength For Pro Medicus

Jul 10 2025 - Australia